Setup, so nobody has to ask: KP · WXT · Japan.
I want to know what the trade-off actually is rather than which option is fashionable.
I would rather have a defensible reason than a marginal improvement.
Which axes does this decision turn on?
The relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.
To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.
Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.
Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.
Price per milligram of measured peptide, not per milligram of label claim.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThis is the question where methodology matters more than the conclusion.
Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.
Concretely, submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.
Compare content, not purity. Purity clusters and content does not.
Answer first: comparing suppliers is only meaningful if the comparison holds the laboratory, the method and the compound constant, and most published comparisons hold none of them.
Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.
More usefully, sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.
Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.
One laboratory, one method, one submission. Otherwise it is not a comparison.
The honest answer is that most claimed differences between reputable suppliers are inside inter-laboratory noise.
Publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.
Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.
Use a fixed documentation checklist rather than an impression.
edited 28 Jul 2026 by klara_novotna — fixed an arithmetic slip in the third paragraph
The short version: same compound, same laboratory, same method, ideally same week — otherwise you are comparing laboratories rather than suppliers.
Lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.
The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.
The caveat is that a comparison is a snapshot of the lots compared, and lots change.
Name the laboratory and the dates or the comparison cannot be reproduced.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.